Johnson & Johnson model projects lower lifetime costs with Impella versus balloon pump in high-risk PCI
- Johnson & Johnson will present 26 Impella heart pump abstracts at TCT 2026, running Oct. 31-Nov. 3 in San Diego.
- A model projects lower lifetime healthcare costs and better quality-adjusted survival versus intra-aortic balloon pumps for heart failure patients undergoing high-risk PCI.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.